Pharmaceutical company Zydus Cadila announced today in a press release its ZyCoV-D plasmid DNA vaccine has cleared preclinical trials and is now approved for human testing.
See the updated status of Zydus Cadila on our vaccine tracker, where we track the status of every COVID-19 under development on a daily basis.
ZyCoV-D received permission from the Drug Controller General of India - CDSCO for Phase I/II clinical trials to take place in India with human subjects. The permission was granted following neutralizing antibody responses in mice, rats, guinea pigs, and rabbits during pre-clinical trials.
The Phase I/II trials are planned for July 2020 and will take place across India in 1000 subjects. The company promotes the safety of their vaccine due in large part to the "non-replicating and non-integrating plasmid carrying the gene of interest."
This news comes just days after Indian rival company Bharat Biotech made claim as the very first Indian company to bring a COVID-19 vaccine to human subjects.